Rigel Pharmaceuticals
RIGL
131 hedge funds and large institutions have $400M invested in Rigel Pharmaceuticals in 2019 Q1 according to their latest regulatory filings, with 16 funds opening new positions, 39 increasing their positions, 29 reducing their positions, and 17 closing their positions.
173% more call options, than puts
Call options by funds: $916K | Put options by funds: $335K
34% more repeat investments, than reductions
Existing positions increased: 39 | Existing positions reduced: 29
10% more capital invested
Capital invested by funds: $365M → $400M (+$35M)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0.21% less ownership
Funds ownership: 9.52% → 9.31% (-0.21%)
6% less first-time investments, than exits
New positions opened: 16 | Existing positions closed: 17
2% less funds holding
Funds holding: 133 → 131 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$3.66M |
| 2 |
Two Sigma Investments
New York
|
+$2.11M |
| 3 |
Marshall Wace
London,
United Kingdom
|
+$1.85M |
| 4 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$1.48M |
| 5 |
Renaissance Technologies
New York
|
+$1.43M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SI
Sofinnova Investments
Menlo Park,
California
|
-$7.78M |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$6.51M |
| 3 |
Goldman Sachs
New York
|
-$4.42M |
| 4 |
AllianceBernstein
Nashville,
Tennessee
|
-$2.63M |
| 5 |
Morgan Stanley
New York
|
-$2.15M |
RIGL Hedge Fund Activity: Q1 2019 in Review
131 of the 4,620 institutional investors tracked by Wall St. Rank reported a position in Rigel Pharmaceuticals (RIGL) for Q1 2019, worth a combined $400M — up 9.6% from $365M a quarter earlier.
Sellers outnumbered buyers: 17 funds closed out of RIGL and 16 opened new positions — a net loss of 1 holder — while 29 trimmed existing stakes and 39 added.
The largest buyer was Vanguard Group, adding an estimated $3.66M. The largest seller was Sofinnova Investments, exiting entirely with an estimated $7.78M sold.
- 131 institutional investors held Rigel Pharmaceuticals (RIGL) as of Q1 2019, down from 133 in Q4 2018.
- Funds reported $400M of Rigel Pharmaceuticals stock for Q1 2019, up 9.6% quarter-over-quarter.
- 16 funds opened new Rigel Pharmaceuticals positions in Q1 2019 and 17 closed out, a net change of -1 holder.
- The largest Rigel Pharmaceuticals buyer in Q1 2019 was Vanguard Group, an estimated $3.66M added.
- The largest Rigel Pharmaceuticals seller in Q1 2019 was Sofinnova Investments, an estimated $7.78M sold.
Based on aggregated 13F filings for Q1 2019.